Table 1 therapeutic targeting of individual AML mutations
From: Molecular landscape and targeted therapy of acute myeloid leukemia
Mutation | Therapeutic target | Inhibitors (phase of clinical trials) |
|---|---|---|
FLT3 | FLT3 | FLT3 tyrosine kinase inhibitors: sorafenib (III), midostaurin (approved), quizartinib (III), crenolanib (III), gilteritinib (III), lestaurtinib (III) Other TKIs: ponatinib (I/II) |
IDH1/2 | IDH1 | Ivosidenib (approved), IDH-305(I), BAY1436032(I), FT-2102(I/II), AG-881(I) |
IDH2 | Enasidenib (approved), AG-881(I) | |
BCL-2 | venetoclax (III) | |
KIT | KIT | TKIs: imatinib, dasatinib (III), ponatinib |
sorafenib, sunitinib, quizartinib | ||
TP53 | TP53 | PANDAS |
BCL-2 | venetoclax | |
MDM2 | MDM2 inhibitors: RG7112 (I) | |
Others | decitabine | |
SF3B1 | SF3b complex | H3B-8800 (I) |